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Abstract Fabry disease is an X-linked inborn error of
glycosphingolipid metabolism caused by quantitative or
qualitative defects in the lysosomal enzyme alfa-Galactosidase
A (aGAL A), ultimately resulting in vital organ dysfunction.
Mainly the kidneys, the heart, and the central nervous system
are involved.While the classical phenotype of Fabry disease is
readily recognizable, screening studies have identified clinical
variants. Here, we report the phenotype associated with the
GLA p.Ala143Thr (c.427G>A) mutation in 12 patients aged
42–83 years. None of the patients had classical Fabry signs
or symptoms as angiokeratoma, hypohidrosis, acroparesthe-
sia, or cornea verticillata. Possible Fabry manifestations were
renal failure (5/12), stroke (7/12), and left ventricular
hypertrophy (5/12), but these were not necessarily attribut-
able to the p.Ala143Thr mutation, as a cardiac biopsy in one
female and left ventricular hypertrophy and kidney biopsies
in two males with renal failure and microalbuminuria lacked
Gb-3 deposits. The literature data on this mutation as well as
data collected in the Fabry Outcome Survey (FOS) database
confirm these findings. The association of renal failure,
stroke, and left ventricular hypertrophy with this mutation
could be the result of selection bias, as most patients were
detected in screening studies.
We conclude that care should be taken with attribution of
vital organ dysfunction to GLA sequence alterations. In case
of the p.Ala143Thr mutation, and possibly also other
mutations associated with an attenuated phenotype, diag-
nostic tools such as biopsy and imaging should critically
evaluate the relation of end-organ failure with Fabry
disease, as this has important consequences for enzyme
replacement therapy.
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Introduction
Fabry disease (FD, MIM ID #301500) is an X-linked
inborn error of glycosphingolipid metabolism caused by
quantitative or qualitative defects in the lysosomal enzyme
alfa-Galactosidase A (aGAL A). As a result, glycosphingo-
lipids, mainly globotriaosylceramide (Gb-3), accumulate in
different cells throughout the body, ultimately resulting in
organ failure (Kint 1970; Brady et al. 1967). Classical FD
has been described as a multisystem disease predominantly
presenting in males with angiokeratoma, hypohidrosis, and
acroparesthesia in childhood, followed by renal failure, left
ventricular hypertrophy, stroke, and premature death in the
fourth and fifth decade of life. Besides these cases,
attenuated forms have been described with a less severe
phenotype and a later onset. In males, a specific mutation,
associated with a significant residual enzyme activity, can
result in a less severe phenotype that presents later in life
(e.g., the “cardiac variants”) (NAKAO et al. 1995; Scheidt
von W et al. 1991). In females, residual enzyme activity can
be the consequence of skewed X-chromosome inactivation.
In the present paper, we present clinical and pathological
data on a series of 12 patients with the p.Ala143Thr
mutation and compare these data with literature data
(9 patients) and data from the Fabry Outcome Survey
(FOS) (20 patients).
Patients and Methods
We retrospectively reviewed the charts of patients with the
p.Ala143Thr mutation diagnosed in our different screening
studies and in the subsequent pedigree analyses (Terryn
et al. 2008; De Schoenmakere et al. 2008). These studies
were conducted according the World Medical Association
Declaration of Helsinki Ethical Principles for Medical
Research Involving Human and were approved by the
Ethics Institution Review Boards of participating centers.
All patients gave written informed consent.
Measurement of aGAL A activity was based on a
technique involving a dried blood spot sampled on
filter paper (DBS) as described by Chamoles et al. (2001).
To validate this technique in our laboratory setting,
we performed an analysis of 50 control samples (non-
nephrology, non-ICU, non-hematology, non-pediatric). In
case of low aGAL A activity, DBS was repeated in a new
blood sample.
In a second part, previously published cases of the p.
Ala143Thr mutation were identified through a PubMed
search from 1966 to September 6, 2011, entering
“p.Ala143Thr”, “A143T,” AND “Fabry Disease” as MESH
terms.
A third part of this study consists of the analysis of FOS
data. FOS – the Fabry Outcome Survey – is a European
outcomes database for patients with Fabry disease who are
receiving, or are candidates for, Enzyme Replacement
Therapy (ERT) with agalsidase alfa. Data from all consent-
ing patients are entered into the database following a
structured clinical assessment by a physician or a
specialized nurse. FOS has been approved by the Ethics
Institution Review Boards of participating centers and all
patients gave written informed consent. All measurements
performed routinely in clinical practice are entered into the
database. Anonymous data are submitted electronically by
participating physicians to the central FOS database. We
summarized baseline available data on all adult (18+)
patients with the p.Ala143Thr mutation in this database.
Kidney Biopsies
If kidney biopsies were available, they were reviewed by a
local pathologist and by a renal pathologist with expertise
in FD (AF). Sections were stained with H & E, PAS, Jones,
Congo Red, toluidine blue, and trichrome.
Results
In total, 41 patients with the GLA p.Ala143Thr mutation
were identified.
Twelve patients (three males and nine females) were
detected through our screening studies and subsequent
pedigree analysis (Table 1). “Classical” symptoms of FD
(angiokeratoma, acroparesthesia, cornea verticillata, and
hypohydrosis) were absent. A significant number of
patients had left ventricular hypertrophy (N ¼ 5) or a history
of stroke (N ¼ 7), but this could be due to a selection bias,
as most of these patients were detected as a result of
screening studies in populations with left ventricular hyper-
trophy or stroke (Terryn et al. 2008, accepted in the
International Journal of Cardiology). Of note, residual
enzyme function could be demonstrated in all patients.
Patient 1, 2, and 5 had a kidney biopsy showing no signs of
Fabry nephropathy. Proteinuria and renal failure in patient 1
could be attributed to diabetic nephropathy. Patient 2 was
detected as a result of pedigree analysis and despite his low
aGAL A he had no signs of FD and was asymptomatic
besides intermittent paresthesias in both arms, that were
aspecific according to an expert neurologist.
One female patient with pronounced left ventricular
hypertrophy (LVH) and heart failure (patient 7) had a
myocardial biopsy showing AL amyloid and no typical
Gb-3 deposition. In our screening studies in high-risk
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populations (Table 2), GLA mutations were detected in nine
apparently unrelated patients, with seven having the GLA
p.Ala143Thr mutation.
The cases with p.Ala143Thr from literature are summar-
ized in Table 3. Only two patients were diagnosed as the
result of symptoms and signs (patient 4 and 7). One patient
(patient 7) had a single angiokeratome. A second patient
(patient 4) had a cramp-fasciculation syndrome. The other
seven patients were diagnosed as the consequence of
screening studies and had no typical Fabry symptoms.
One male (patient 4) had a kidney biopsy. Typical Fabry
inclusions were only noted in a few collecting ducts and
distal tubules but not in podocytes or in the endothelium.
Another male (patient 9) had a nephrectomy after trans-
plantation because of bilateral renal cell carcinoma.
Histological examination of the nonmalignant renal tissue
showed chronic glomerulonephritis, hyalinization, and
severe arteriosclerosis, but no lesions typical for Fabry
disease.
The FOS data are summarized in Table 4. Among 1933
registered Fabry patients, 20 adults (12 females and 8 males)
from the United Kingdom, Germany, France and Belgium
had the p.Ala143Thr mutation. The median baseline eGFR
(MDRD) in female patients was 83 mL/min/1.73 m2 at a
mean age of 39. In males, this was 74 mL/min for a median
age of 45.
Only limited data were available on the subsequent
evolution of kidney function in these patients before ERT
was started. In females, median delta eGFR (mL/min/1.73
m2/year) was –3.3, which is comparable with literature data
on Fabry nephropathy. In males, however, median delta
eGFR (mL/min/year) was +1.35 mL/min/1.73 m2/year,
which is in contradiction with expected kidney function
deterioration in Fabry males which is up to –12.2 mL/min/
1.73 m2/year (Branton et al. 2002).
Many patients (male and female) had micro-albuminuria.
Only three had macro-albuminuria (> 300 mg/24 h). The
cause of albuminuria was not clear, as only two patients had
been biopsied. The male (patient 16) did not show Fabry
nephropathy but lupus nephritis, and was successfully
treated with immunosuppressive therapy. Stroke was
mentioned in only one 80-year-old female (patient 8); at
this age, stroke cannot simply be attributed to FD alone.
Discussion
The p.Ala143Thr mutation is a previously reported mis-
sense mutation: resulting from a G to A transition at
nucleotide position 247 in exon 3, leading to an Alanine to
Threonine substitution and has been reported as being
pathogenic (Eng et al. 1997).
The p.Ala143Thr mutation was first reported in 1997
(Eng et al. 1997). The propositus was a 1-month-old male
infant serendipitously found to have deficient aGAL A
activity with no family history of FD. It was concluded in
the same paper that the phenotype associated with this
mutation was unknown. In 2002, this mutation was
detected in patients as a result of screening in dialysis
patients (Spada 2002 JIMD abstract). In a second abstract
(Spada 2003), the same author considered this mutation to
be related to late-onset end-stage renal disease. From that
time, we read in literature this is a “known pathogenic
mutation,” but it was not supported with biopsy data as
proof of its pathogenicity. The association of this mutation
with renal failure, as in our screening studies (Table 2) in
renal failure or left ventricular hypertrophy, might thus be
the result of selection bias.
In vitro expression of this mutant allele in COS 7 cells
has been studied (Spada et al. 2006). There is 36 % of
Table 2 Screening in high-risk groups in Flanders
Hemodialysisa Kidney transplantationb Left ventricular hypertrophyc Total high-risk population
Female (N) 742 395 178 178
Mutation in females (N) (%) 2 (0.27%) 0 3 (1.7%) 5 (0.38%)
Male (N) 180 278 362 820
Mutation in females (N) (%) 1 (0.56%) 1 (0.36%) 2 (0.55%) 4 (0.49%)
Total patients (N) 922 673 540 2135
Mutations (N) (%) 3 (0.33%) 1 (0.15%) 5 (0.93%) 9 (0.42%)
GLA p.Ala143Thr (c. 427G>A) 2 1 4 7 (0.33%)
GLA p.Trp236Arg (c.706T>C) 1 0 0 1 (0.046%)
GLA p.Ala5Glu (c.44C>A) 0 0 1 1 (0.046%)
aWim Terryn et al. (2008)
b De Schoenmakere et al. (2008)
c Terryn W et al. (2012) Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. Accepted (June
2012) by the "International Journal of Cardiology”
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expressed aGAL Awild-type activity which is in agreement
with residual enzyme function in our patients. The finding
of a low aGAL A activity however is not directly related to
FD. We found that the p.Ala143Thr mutation indeed is
associated with a low aGAL A activity, but its contribution
to the phenotype of our patients (stroke, renal failure, left
ventricular hypertrophy) is unclear. We performed three
kidney biopsies, all lacking typical Gb-3 deposits which are
universally present in Fabry patients (Noël et al. 2012).
Moreover, among the remaining patients described in this
study, we could not find one patient with this mutation and
renal failure in whom significant renal Fabry disease was
proven by kidney biopsy. In the sphingolipidosis, the ratio
of substrate influx into the lysosome and the capacity of the
degrading system determines the storage and as such the
course and severity of the disease. This is treated in
quantitative terms by the so-called threshold theory
(Kolter 2011). Only the decrease of enzyme activity below
the critical threshold value causes storage of the
corresponding lipid substrate. Decrease of enzyme activity
to the calculated threshold value does not influence the
turnover rate of the substrate (as above this threshold, there
is no (linear) relation between enzyme activity and
turnover) and pathological storage occurs only below this
level. With the exception of acid ceramidase, a decrease of
enzyme activity to values of 20 % of normal cells, a typical
range for heterozygote carriers of inherited diseases, has no
impact on the turnover rate (Kolter 2011).
Our findings corroborate these findings, as we found no
deposition of Gb-3 in the lysosomes of the cells of our patients
with the p. Ala143Thr mutation. On the basis of the “thres-
hold theory” and the in vitro studies of Spada et al. (2006),
Table 4 FOS data on adult patients with the p.Ala143Thr mutation
Patient;
code
FOS Sex
Age at
baseline
aGAL A
(nmol/h/
mL)a
eGFR before start
of ERT (MDRD,
mL/min/1.73 m2)
Proteinuria before
start of ERT
(mean) (mg/24 h)
Follow up
before ERT
(months)
Delta eGFR
(mL/min/
1. 73 m2/
year)
Kidney
biopsy Stroke ERT
1 F 32 2.7a 107 165 30 3,3 No No Yes
2 F 55 4.9a 98 230 5 +16.1 No No Yes
3 F 21 0,48b 108 61 51 6.1 No No Yes
4 F 29 0,22b 83 102 10 +7.0 No No Yes
5 F 33 0,17b 71 107 11 7.6 No No Yes
6 F 38 0,79b 82 110 22 1.6 No No No
7 F 47 NA 71 1802 NA NA No No Yes
8 F 80 NA 27 NA 30 5.6 Yes Yes No
9 F 51 NA 85 NA NA NA No No No
10 F 64 0,69b 67 140 8 11.5 No No Yes
11 F 24 NA NA NA NA NA NA NA Yes
12 F 40 12a 109 NA 1 +69.5 No No No
Median F 39 83 3.3
13 M 26 0.5c 177 NA 6 2.0 No No Yes
14 M 62 0,14a 67 303 21 +5.6 No No Yes
15 M 52 NA 74 120 10 +4.7 No No Yes
16 M 40 0,25b 15 2755 2 +91.3 Yes No NA
17 M 68 0,15b 43 185 13 7.2 No No Yes
18 M 44 22d 112 137 NA 8,0 No No Yes
19 M 46 13d 130 128 NA NA No No Yes
20 M 45 2.4 NA 41e NA NA No No Yes
Median M 45 74 +1.35
NA Not available, MDRD Modification of diet in renal disease, ERT Enzyme replacement therapy
a (nmol/h/mL) normal values 3.4–13
b (nU/mg) normal values 0.36–0.84 mU/mg
cMeasured shortly at birth
d nmol/MU/mg protein normal >33
emg/gr creatinine
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this could be predicted, as the in vitro expression of
aGAL A in this genotype was 36 % of the wild type
expression, which is well over the 20 % mentioned by
Kolter 2011.
In FOS, kidney function in patients with p.Ala143Thr
remains well preserved in males until their 40s, which is in
contradiction with studies on natural history (Branton et al.
2002). Unfortunately, we have no biopsy data in all of these
patients, so we cannot ascertain or exclude renal FD in
many patients.
Attenuated Fabry phenotypes lacking the classical FD
symptoms have been described as a consequence of
residual aGAL A activity. Some mutations result in residual
aGAL A activity. This has been described to result in
“cardiac variants” that present later in life, with predomi-
nantly cardiac manifestations (Scheidt von W et al. 1991).
Most of the female patients in this study could be regarded
as “variants”; they have significant residual enzyme
function, no classical FD symptoms, and mostly cardiac
and neurological symptoms.
On the other hand, as FD remains the subject of
screening studies in high-risk populations including patients
with renal failure and/or stroke, there is a danger of
misdiagnosis as a result of selection bias, especially as the
p.Ala143Thr mutation was not only detected in screening
studies in Belgium (Terryn et al. 2008; De Schoenmakere
et al. 2008; Brouns et al. 2010) but also in newborn
screenings in Italy (Spada et al. 2006), Taiwan (Lin et al.
2009) Austria (Mechtler et al. 2012), and in other screening
studies (Monserrat et al. 2007; Elliott et al. 2011).
The prevalence of the p.Ala143Thr mutation in our high-
risk populations (0.33 %, Table 3) is almost 20 times higher
than in a European newborn population (0.017 %, Mechtler
et al. 2012). Low a-aGAL A activity could be one cofactor
contributing to endothelial stress, provoking stroke, renal
failure, or other signs, and symptoms classically associated
with FD. The lack of Gb-3 deposits on electron microscopy
does not preclude high intracellullar (lyso)-Gb3 levels that
could be pathogenic and cause endothelial cell dysfunction
(Namdar et al. 2012), though this should be confirmed with
further studies.
Despite the coexistence of renal failure, proteinuria, and
low aGAL A activity in patient 1 from our database
(Table 1), the diagnosis of Fabry nephropathy was offset by
the biopsy that showed a typical case of diabetic nephropa-
thy. Proteinuria and renal failure in patient 16 in the FOS
database (Table 4) was secondary to lupus nephritis. The
cardiac biopsy in patient 7 from our own database (Table 1)
with LVH and heart failure showed AL amyloid. These
examples prove that before accepting the diagnosis of FD,
confirmation of a mutation and diminished enzyme activity
are needed, as well as comprehensive clinical and patho-
logical workup of the patients, where biopsies of the
involved organ, next to other diagnostics tools as MRI in
left ventricular hypertrophy, should confirm the diagnosis.
Only two patients with the p.Ala143Thr in FOS were
reported to have had a kidney biopsy, in spite of a larger
number of patients with renal failure. Nevertheless, most of
the included patients were treated with ERT. This expensive
treatment is possibly not warranted in these patients.
In stroke, establishing a diagnosis of FD is even more
difficult as is the case also in several of our own cases, as
biopsy of the affected organ is impossible. Diagnosis is
especially difficult when other typical features of FD are
lacking, as is the case for the p.Ala143Thr mutation.
It has been proposed by expert panels to start treatment
in all adult (>16 years) male Fabry patients, and in all
patients, pediatric, male, or female, “as soon as clinical
signs and symptoms are observed” (Eng et al. 2006). In our
cases, however, we have no knowledge on the contribution
of the enzymatic defect to the patients’ morbidity and no
reliable prognostic data are available on the evolution in
case of an “atypical” variant like the p.Ala143Thr. It is even
questionable if these patients have Fabry disease at all; it
has been suggested to call such mutations, biochemically
true positive but clinically false positive, as “fringe
mutations” (Houge et al. 2011). Moreover, ERT has been
studied in the classical phenotype, but there are no studies
on the effects in the atypical variants.
The inclusion of patients with the p.Ala143Thr or other
mutations associated with an attenuated phenotype (e.g.,
N215S or p.Asn215Ser, Branton et al. 2002) in studies on
the effectiveness of ERT could confound results and should
be studied separately. The place of ERT in patients with the
p.Ala143Thr mutation is still unclear and should be the
subject of close study. The currently available databases such
as the industry-sponsored FOS cannot answer this question.
An independent international database with mandatory data
collection could provide quality data for further study.
Based on our data, we conclude that the expressivity of
the p.Ala143Thr mutation is extremely variable. The
presence of this mutation is not to be directly associated
with pathology, and we have no compelling data that label
this mutation as “pathogenic.” At most, it is “possibly”
pathogenic. As a consequence, biopsy and clinical data
should be collected in order to be able to understand the
natural evolution and to decide on the need for ERT.
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